John P Leonard

John P Leonard

UNVERIFIED PROFILE

Are you John P Leonard?   Register this Author

Register author
John P Leonard

John P Leonard

Publications by authors named "John P Leonard"

Are you John P Leonard?   Register this Author

100Publications

3051Reads

28Profile Views

A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.

Leuk Lymphoma 2019 Dec 23;60(12):2917-2921. Epub 2019 May 23.

Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and NewYork Presbyterian Hospital, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1612062DOI Listing
December 2019

Reply to T.M. Weis et al.

J Clin Oncol 2019 Nov 18;37(31):2953. Epub 2019 Sep 18.

Nancy L. Bartlett, MD, Washington University School of Medicine, St Louis, MO; Wyndham H. Wilson, MD, PhD, National Institutes of Health, Bethesda, MD; and John P. Leonard, MD, Weill Medical College of Cornell University, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01617DOI Listing
November 2019

Lymphoma Study Titles on ClinicalTrials.gov Lack Details Necessary for Study Identification.

Clin Lymphoma Myeloma Leuk 2019 Nov 21. Epub 2019 Nov 21.

Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.11.011DOI Listing
November 2019

New developments in the treatment of follicular lymphoma.

Authors:
John P Leonard

Rinsho Ketsueki 2019 ;60(9):1199-1204

Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.60.1199DOI Listing
October 2019

Illness Understanding and Advance Care Planning in Patients with Advanced Lymphoma.

J Palliat Med 2019 Oct 18. Epub 2019 Oct 18.

Department of Medicine, Weill Cornell Medicine, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jpm.2019.0311DOI Listing
October 2019

Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma.

Leuk Lymphoma 2019 Sep 8;60(9):2255-2263. Epub 2019 Mar 8.

Department of Hematology and Oncology, Winship Cancer Institute, School of Medicine, Emory University , Atlanta , GA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1574006DOI Listing
September 2019

De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma.

Authors:
John P Leonard

J Clin Oncol 2019 May 2;37(15):1267-1269. Epub 2019 Apr 2.

1 Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.19.00445
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00445DOI Listing
May 2019

Bone marrow biopsies not indicated for response assessment in follicular lymphoma trials regardless of type of imaging study - Response to Adams and Kwee.

Br J Haematol 2019 02 29;184(3):466-467. Epub 2018 Jan 29.

Department of Medicine, Division of Hematology and Oncology, Meyer Cancer Center, Weill Cornell Medical College and New York-Presbyterian Hospital, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15113DOI Listing
February 2019

A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma.

Br J Haematol 2018 12 19;183(5):828-831. Epub 2017 Dec 19.

Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15057DOI Listing
December 2018

Where to start? Upfront therapy for follicular lymphoma in 2018.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):185-188

Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246009PMC
November 2018

Sequencing of therapies in relapsed follicular lymphoma.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):189-193

Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245973PMC
November 2018

Novel immunotherapy approaches to follicular lymphoma.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):194-199

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.194DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245999PMC
November 2018

DLBCL Cell of Origin: What Role Should It Play in Care Today?

Oncology (Williston Park) 2018 09;32(9):445-9

View Article

Download full-text PDF

Source
September 2018

Management of Relapsed and Refractory Hodgkin Lymphoma in 2018.

JAMA Oncol 2018 08;4(8):1120-1121

Meyer Cancer Center, Division of Hematology and Medical Oncology, Weill Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.1767DOI Listing
August 2018

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

N Engl J Med 2018 04;378(15):1396-1407

From the Lymphoid Malignancies Branch (R.S., D.W.H., J.D.P., J.Q.W., S.R., M.K., R.M.Y., A.L.S., D.J.H., W. Xiao, X.Y., Y.Y., H.Z., W. Xu, W.H.W., L.M.S.), the Biometric Research Program, Division of Cancer Diagnosis and Treatment (G.W.W.), and the Laboratory of Pathology, Center for Cancer Research (E.S.J., S.P.), National Cancer Institute, and the Office of Intramural Research, Center for Information Technology (C.A.J., X.L., B.Z., W.D.), National Institutes of Health, Bethesda, and the Cancer Research Technology Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (B.T., J.S., Y.Z., D.R.S.) - all in Maryland; the Department of Pathology, City of Hope National Medical Center, Duarte, CA (W.C.C.); the BC Cancer Agency, Vancouver, BC (R.D.G., J.M.C.), and the University Health Network, Laboratory Medicine Program, Toronto General Hospital and University of Toronto, Toronto (J.D.) - both in Canada; the Hospital Clinic of Barcelona, University of Barcelona, Institute for Biomedical Research August Pi I Sunyer, Barcelona (E.C., A.L.-G.); the Institute of Pathology, University of Würzburg, and Comprehensive Cancer Center Mainfranken, Würzburg (A.R.), and the Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart (G.O.) - all in Germany; the Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ (L.M.R.); the National Cancer Centre of Singapore, Singapore (K.T.K.W.); Memorial Sloan Kettering Cancer Center (A.D.Z.) and Weill Cornell Medicine (J.P.L.) - both in New York; the Department of Medicine, Washington University School of Medicine, St. Louis (N.L.B.); and the Alliance for Clinical Trials in Oncology, Chicago (A.D.Z., J.P.L., N.L.B.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1801445
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1801445DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010183PMC
April 2018

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

J Clin Oncol 2018 03 22;36(7):697-703. Epub 2018 Jan 22.

Mazyar Shadman, Ajay K. Gopal, David G. Maloney, and Oliver W. Press, University of Washington and Fred Hutchinson Cancer Research Center; Hongli Li and Michael LeBlanc, SWOG Statistical Center, Seattle, WA; Lisa Rimsza, Mayo Clinic Arizona, Scottsdale; Catherine M. Spier, University of Arizona, Tucson, AZ; John P. Leonard, Weill Cornell Medical College, New York; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; Mark S. Kaminski, University of Michigan Health System, Ann Arbor, MI; Rita M. Braziel, Oregon Health & Science University, Portland, OR; Bruce D. Cheson, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC; Shaker Dakhil, University of Kansas School of Medicine-Wichita, Wichita, KS; Sonali M. Smith, University of Chicago Medicine, Chicago, IL; and Richard I. Fisher, Fox Chase Cancer Center and Temple University School of Medicine, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.5083
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.5083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553811PMC
March 2018

The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.

Leuk Lymphoma 2018 01 2;59(1):256-258. Epub 2017 Jun 2.

a Department of Medicine, Division of Hematology and Oncology , Meyer Cancer Center, Weill Cornell Medicine and New York-Presbyterian Hospital , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1323270DOI Listing
January 2018

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

J Clin Oncol 2017 Nov 1;35(31):3538-3546. Epub 2017 Sep 1.

John P. Leonard, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY; Kathryn S. Kolibaba, Compass Oncology, Vancouver, WA; Kathryn S. Kolibaba and Nicholas J. DiBella, US Oncology Research, The Woodlands; Robert Collins, University of Texas Southwestern Medical Center, Dallas, TX; James A. Reeves, Florida Cancer Specialists, Fort Myers; Julio Hajdenberg, University of Florida Health Cancer Center at Orlando Health, Orlando, FL; Anil Tulpule, Keck Medicine of University of Southern California; Sven de Vos, University of California at Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles; Tatjana Kolevska, Kaiser Permanente Medical Center Northern California, Vallejo; Robert Robles, Bay Area Cancer Research Group (Diablo Valley Medical Group), Pleasant Hill; Andrew Horodner, Cancer Care Associates Medical Group, Redondo Beach, CA; Ian W. Flinn, Sarah Cannon Research Institute, Nashville, TN; Christopher R. Flowers, Winship Cancer Institute of Emory University, Atlanta, GA; Nicholas J. DiBella, Rocky Mountain Cancer Centers, Aurora, CO; Steven W. Papish, Summit Medical Group MD Anderson Cancer Center, Camden, NJ; Parameswaran Venugopal, Rush University Medical Center, Chicago, IL; Amir Tabatabai, York Cancer Center/Cancer Care Associates of York, York, PA; and Jaehong Park, Rachel Neuwirth, George Mulligan, Kaveri Suryanarayan, and Dixie-Lee Esseltine, Millennium Pharmaceuticals, Cambridge, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.2784
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.2784DOI Listing
November 2017

Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials.

Br J Haematol 2017 10 5;179(2):242-245. Epub 2017 Jul 5.

Department of Medicine, Division of Hematology and Oncology, Meyer Cancer Center, Weill Cornell Medical College and New York-Presbyterian Hospital, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14839DOI Listing
October 2017

The potential for chemotherapy-free strategies in mantle cell lymphoma.

Blood 2017 10 12;130(17):1881-1888. Epub 2017 Sep 12.

Division of Hematology and Medical Oncology and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-05-737510DOI Listing
October 2017

Lymphoma "benchmark" or "bench-smudge"?

Blood 2017 10;130(16):1778-1779

WEILL CORNELL MEDICINE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-08-800730DOI Listing
October 2017

Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia.

J Clin Oncol 2017 Aug 27;35(23):2708-2715. Epub 2017 Jun 27.

All authors: Weill Cornell Medicine and New York Presbyterian Hospital, New York NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.6745DOI Listing
August 2017

The Uncertainties of Rituximab and Related Therapies, 20 Years After Approval.

Oncology (Williston Park) 2017 05;31(5):412, 414

View Article

Download full-text PDF

Source
May 2017

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

J Natl Cancer Inst 2017 04 31;109(4). Epub 2016 Dec 31.

Affiliations of authors: NYU Perlmutter Cancer Center, New York, NY (CSD); BC Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada (JMC); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY (JWF); Department of Medicine, Weil Cornell University, New York, NY (JPL); Oncology Division, Department of Medicine, Washington University, St. Louis, MO (BSK, NLB); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), Tufts Cancer Center and Division of Hematology/Oncology, Tufts University School of Medicine, Boston, MA (AME); Stanford Cancer Institute, Stanford University Medical School, Stanford, CA (RTH); Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Columbia University Medical Center, New York, NY (KMK); Department of Medicine, University of Arizona Cancer Center, Tucson, AZ (DOP); Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY (AY); Department of Radiology, Mount Sinai Hospital, New York, NY (LK).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059238PMC
April 2017

Recommendations for Clinical Trial Development in Follicular Lymphoma.

J Natl Cancer Inst 2017 03 31;109(3). Epub 2016 Dec 31.

Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw255DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059137PMC
March 2017

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

J Natl Cancer Inst 2017 01 31;109(1). Epub 2016 Dec 31.

Affiliations of authors: Division of Hematology and Medical Oncology, Oregon Health and Science (OHSU) University Knight Cancer Institute, Portland, OR (SES); Clinical Research Division, Fred Hutchinson Cancer Research Center/ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA (BGT, AKG); Department of Medicine, Weill Cornell Medicine, New York, NY (PM, JPL); John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ (AHG); Department of Medicine III, Klinikum der Universität München, Campus Grosshadern, Munich, Germany (MPD); Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (ML); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health, Bethesda, MD (LB); HIV and AIDS Malignancy Branch, Center for Cancer Research, and Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (RFL); Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH (MRS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059122PMC
January 2017

General Biomarker Recommendations for Lymphoma.

J Natl Cancer Inst 2016 12 16;108(12). Epub 2016 Dec 16.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ (LR), Department of Pathology and Laboratory Medicine, University of North Carolina Medical School, Chapel Hill, NC (YF), Center for Cancer Research, National Cancer Institute, Bethesda, MD (LMS), Department of Medicine, Weill Cornell Medical College, New York, NY (AM), Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada (RG), Clinical Cancer Research Unit, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada (MC), Coordinating Center for Clinical Trials, National Cancer Institute, Bethesda, MD (LB), Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE (KF), Department of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH (ED), Department of Pathology, City of Hope Medical Center, Duarte, CA (JWCC), Biometrics Research Branch, National Cancer Institute, Bethesda, MD (LM), Department of Medicine, Weill Cornell Medicine, New York, NY (JPL), Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK), Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (RFL), Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF), Department of Radiology, Mount Sinai Medical Center New York, NY (LK).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080362PMC
December 2016

Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.

J Natl Cancer Inst 2016 12 16;108(12). Epub 2016 Dec 16.

Department of Medicine, Mayo Clinic, Rochester, MN (GSN); Department of Internal Medicine, Ohio State University, Columbus, OH (KAB); Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Coordinating Center for Clinical Trials (LB), Division of Cancer Treatment and Diagnosis (RFL), and Center for Cancer Research (WHW), National Cancer Institute, National Institute of Health, Bethesda, MD; Division of Oncology, University of Washington, Seattle WA (DGM); British Colombia Cancer Agency, Vancouver, BC (LHS); Department of Medicine, University of Virginia, Charlottesville, VA (MEW); Department of Medicine, Weil Cornell University, New York, NY (JPL); Department of Medicine, University of Chicago, Chicago, IL (SMS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080361PMC
December 2016

Behavioral and physiological characterization of PKC-dependent phosphorylation in the Grin2a∆PKC mouse.

Brain Res 2016 09 15;1646:315-326. Epub 2016 Jun 15.

Department of Biological Sciences, University of Illinois at Chicago, IL 60607, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brainres.2016.06.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976052PMC
September 2016

Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.

Cell Cycle 2016 Sep 15;15(17):2241-7. Epub 2016 Jul 15.

a Division of Hematology and Medical Oncology, Department of Medicine and Meyer Cancer Center, Weill Cornell Medicine , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2016.1207839DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004704PMC
September 2016

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

J Clin Oncol 2016 06 11;34(17):2020-7. Epub 2016 Apr 11.

Oliver W. Press, Fred Hutchinson Cancer Research Center, and the University of Washington; Hongli Li and Michael LeBlanc, Fred Hutchinson Cancer Research Center, Seattle, WA; Heiko Schöder, David J. Straus, Craig H. Moskowitz, and Ariela Noy, Memorial Sloan Kettering Cancer Center; John P. Leonard, Weill Cornell Medical College and New York Presbyterian Hospital, New York City; Paul M. Barr and Jonathan W. Friedberg, University of Rochester Medical Center, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett and Brad S. Kahl, Washington University School of Medicine, St. Louis, MO; Andrew M. Evens, Tufts Medical Center; Ann S. LaCasce, Dana-Farber Cancer Institute, Boston, MA; Erik S. Mittra, Stanford University Medical Center, Stanford, CA; John W. Sweetenham, Huntsman Cancer Hospital, Salt Lake City, UT; Michelle A. Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Michael V. Knopp, The Ohio State University, Columbus; Eric D. Hsi, Cleveland Clinic Foundation; James R. Cook, Cleveland Clinic, Cleveland, OH; Mary Jo Lechowicz, Winship Cancer Institute of Emory University, Atlanta, GA; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC; Bruce D. Cheson, Georgetown University Hospital, Washington DC; and Richard I. Fisher, Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.1119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966513PMC
June 2016

CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma.

Clin Lymphoma Myeloma Leuk 2016 Apr 4;16(4):191-6. Epub 2016 Jan 4.

GlaxoSmithKline, Collegeville, PA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.12.011DOI Listing
April 2016

Hepatosplenic T-Cell Lymphoma Mimicking Acute Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2016 Mar 26;16(3):e47-50. Epub 2015 Nov 26.

Division of Hematopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://www.omicsgroup.org/journals/hepatosplenic-tcell-lymph
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S215226501501412
Publisher Site
http://dx.doi.org/10.1016/j.clml.2015.11.019DOI Listing
March 2016

Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma.

Clin Lymphoma Myeloma Leuk 2016 Mar 21;16(3):117-21. Epub 2015 Dec 21.

Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.12.006DOI Listing
March 2016

Lenalidomide plus Rituximab for Mantle-Cell Lymphoma.

N Engl J Med 2016 02;374(8):793

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1515465DOI Listing
February 2016

Foraging decisions in wild versus domestic Mus musculus: What does life in the lab select for?

Behav Processes 2016 Jan 6;122:43-50. Epub 2015 Nov 6.

Department of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beproc.2015.10.020DOI Listing
January 2016

Idelalisib-associated Colitis: Histologic Findings in 14 Patients.

Am J Surg Pathol 2015 Dec;39(12):1661-7

*Department of Pathology and Laboratory Medicine †Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000522DOI Listing
December 2015

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).

J Clin Oncol 2015 Nov 24;33(31):3635-40. Epub 2015 Aug 24.

John P. Leonard, Meyer Cancer Center, Weill Cornell Medical College and New York Presbyterian Hospital, New York; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Sin-Ho Jung, Jeffrey Johnson, and Brandelyn N. Pitcher, Alliance Statistics and Data Center, Duke University, Durham, NC; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Kristie A. Blum, Ohio State University Medical Center, Columbus, OH; Jeffrey K. Giguere, Greenville Community Clinical Oncology Program, Greenville, SC; and Bruce D. Cheson, Georgetown University Hospital, Washington, DC.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/08/21/JCO.2014.59
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.59.9258
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.9258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622102PMC
November 2015

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

N Engl J Med 2015 Nov;373(19):1835-44

From the Meyer Cancer Center, Division of Hematology and Medical Oncology (J.R., P.M., R.R.F., A.R., J.L., O.K., M.C., J.P.L.), and Division of Biostatistics and Epidemiology (P.C.), Weill Cornell Medical College and New York-Presbyterian Hospital, New York; Moffitt Cancer Center, Tampa, FL (B.S.); University of Pennsylvania Abramson Cancer Center, Philadelphia (S.J.S., J.S.); and the University of Chicago Medical Center, Chicago (S.M.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1505237DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710541PMC
November 2015

α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.

Am J Pathol 2015 Mar 29;185(3):651-65. Epub 2014 Dec 29.

Department of Pathology, Genzyme Corporation, a Sanofi Company, Framingham, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2014.11.004DOI Listing
March 2015

A roadmap for discovery and translation in lymphoma.

Blood 2015 Mar;125(13):2175-7

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-01-623777DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375113PMC
March 2015

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.

Cancer Discov 2014 Sep 31;4(9):1022-35. Epub 2014 Jul 31.

Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York. Graduate Program in Immunology and Microbial Pathogenesis, Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-0098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155003PMC
September 2014

Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP.

Hematology Am Soc Hematol Educ Program 2013 ;2013:591-5

1Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY.

View Article

Download full-text PDF

Source
http://www.asheducationbook.org/cgi/doi/10.1182/asheducation
Publisher Site
http://dx.doi.org/10.1182/asheducation-2013.1.591DOI Listing
July 2014

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

J Clin Oncol 2014 Jun 5;32(17):1797-803. Epub 2014 May 5.

Ronald Levy, Andrew J. Gentles, Chih Long Liu, Robert Tibshirani, and Ash A. Alizadeh, Stanford University Medical Center, Palo Alto; Christos E. Emmanouilides and John M. Timmerman, University of California Los Angeles Medical Center, Los Angeles; Lori A. Kunkel, Diane E. Ingolia, and Dan W. Denney Jr, Genitope, Fremont, CA; Kristen N. Ganjoo and Michael J. Robertson, Indiana University Medical Center, Indianapolis, IN; John P. Leonard, Weill Medical College of Cornell University, New York, NY; Julie M. Vose, University of Nebraska Medical Center, Omaha, NE; Ian W. Flinn and Richard F. Ambinder, Johns Hopkins University Oncology Center, Baltimore, MD; Joseph M. Connors, British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, British Columbia; Neil L. Berinstein, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario; Andrew R. Belch, Cross Cancer Institute, Edmonton, Alberta, Canada; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Craig Nichols, Oregon Health Science University, Portland, OR; Stephanie A. Gregory, Rush University Medical Center, Chicago, IL; Brian K. Link, University of Iowa Hospitals and Clinics, Iowa City, IA; David J. Inwards, Mayo Clinic, Rochester, MN; Arnold S. Freedman, Dana-Farber Cancer Institute, Boston, MA; and Jeffrey V. Matous, Rocky Mountain Cancer Centers, Denver, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.43.9273DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039868PMC
June 2014

Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results.

Clin Lymphoma Myeloma Leuk 2014 Apr 18;14(2):107-13. Epub 2013 Nov 18.

Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.10.002DOI Listing
April 2014

Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.

J Clin Oncol 2013 Nov 16;31(32):4132-9. Epub 2013 Sep 16.

Andrew M. Evens, Tufts University School of Medicine, Boston; Aimee Kroll-Desrosiers, University of Massachusetts Medical School, Worcester, MA; Ranjana Advani and Stavroula Otis, Stanford University Medical Center, Stanford, CA; Oliver W. Press and Linda M. Parker, Fred Hutchinson Cancer Research Center, Seattle, WA; Izidore S. Lossos, Liat Nadav Dagan, and Jose Sandoval, University of Miami School of Medicine, Miami, FL; Julie M. Vose, University of Nebraska Medical Center, Omaha, NE; Francisco J. Hernandez-Ilizaliturri, Roswell Park Cancer Institute, Buffalo; Ramsey Abdallah and John P. Leonard, Weill Cornell Medical College, New York, NY; Barrett K. Robinson, Indiana University School of Medicine, Indianapolis, IN; Jessica L. Yarber and Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; Kristie A. Blum, The Ohio State University, Columbus, OH; Christopher R. Flowers, Emory University, Atlanta, GA; Thomas M. Habermann, Mayo Clinic, Rochester, MN; and Nancy L. Bartlett, Washington University School of Medicine, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.8220DOI Listing
November 2013

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

Cancer Discov 2013 Sep 16;3(9):1002-19. Epub 2013 Aug 16.

1Division of Hematology and Oncology, Department of Medicine, 2Division of Biostatistics and Epidemiology, Department of Public Health, 3Weill Cornell Cancer Center, and Departments of 4Pathology and 5Pharmacology, Weill Cornell Medical College, Cornell University, New York, New York; 6Section of Hematology/Oncology, Department of Medicine, The University of Chicago; Department of Pathology, Northwestern University, Chicago, Illinois; 8Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, University of Montreal, Montreal, Quebec; 9Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia, Canada; 10IBM Research, Rio de Janeiro, Brazil; and 11Department of Oncological Sciences, University of Turin, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770813PMC
September 2013

Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.

Blood 2013 Jun 30;121(26):5192-202. Epub 2013 Apr 30.

Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2013-03-49
Publisher Site
http://dx.doi.org/10.1182/blood-2013-03-490763DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695363PMC
June 2013

Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma?

Authors:
John P Leonard

Clin Adv Hematol Oncol 2012 Aug;10(8):540-2

New York Presbyterian Hospital, New York, New York, USA.

View Article

Download full-text PDF

Source
August 2012

Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen.

Hematology 2012 Apr;17 Suppl 1:S90-2

Center for Lymphoma and Myeloma, Weill Cornell Medical College, The New York-Presbyterian Hospital, New York, NY, USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1179/102453312X13336
Publisher Site
http://dx.doi.org/10.1179/102453312X13336169155970DOI Listing
April 2012

Splenic lymphomas: is there still a role for splenectomy?

Oncology (Williston Park) 2012 Feb;26(2):204, 206

Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, USA.

View Article

Download full-text PDF

Source
February 2012